e-Therapeutics plc Director/PDMR Shareholding (7794A)
03 January 2018 - 6:00PM
UK Regulatory
TIDMETX
RNS Number : 7794A
e-Therapeutics plc
03 January 2018
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY
Oxford, UK, 3 January 2018 - e-Therapeutics plc (AIM: ETX), the
drug discovery company, announces that on 2 January 2018 Professor
Trevor Jones (Non-Executive Director) subscribed for a total of
59,460 new ordinary shares of 0.1p each in the Company (the "New
Ordinary Shares") at a price of 9.25 pence per share. The
subscription monies paid for the New Ordinary Shares represent 50%
of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 1 July 2017 to 31 December 2017.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur on 8 January 2018. The New Ordinary Shares will
rank pari passu in all respects with the Company's existing
ordinary shares in issue.
Following Admission, Professor Jones will be interested in a
total of 321,721 ordinary shares of 0.1p in the Company,
representing approximately 0.12% of the Company's issued share
capital.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 268,530,866. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The Company previously announced that on 5 October 2016
Professor Jones entered into a binding contractual arrangement with
the Company under which he agreed, with effect from 1 October 2016,
to invest 50% of his annual Non-Executive Director fees net of tax
in new e-Therapeutics' ordinary shares.
The new shares will be issued to Professor Jones on the first
business day after 31 December and 30 June in each year. The
subscription price to be paid will be the average of the closing
mid-market price for the five business days prior to the date of
issue. The terms pursuant to which Professor Jones will purchase
the shares are fixed, and he has irrevocably committed to such
terms.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Trevor Jones
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Non-Executive Director
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name e-Therapeutics plc
--- ------------------------ ----------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary Shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------ ----------------------------------
c) Price(s) and 59,460 ordinary shares at a price
volume(s) of 9.25 pence per share
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 2 January 2018
--- ------------------------ ----------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ ----------------------------------
For further information, please contact:
E-Therapeutics plc Tel: +44 (0) 1993
Ray Barlow, Chief Executive 883 125
Officer www.etherapeutics.co.uk
Steve Medlicott, Finance
Director
Numis Securities Limited Tel: +44 (0) 207
Michael Meade/Freddie Barnfield 260 1000
(Corporate Finance) www.numis.com
James Black (Corporate
Broking)
Instinctif Partners Tel: +44 (0) 207
Melanie Toyne Sewell/Alex 457 2020
Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
We are an Oxford-based company with a unique and powerful
computer-based drug discovery platform and a specialised approach
to network biology.
Our novel methodology and our Discovery Engine allow us to
discover new and better drugs in a more efficient and effective
way.
e-therapeutics is headquartered in Oxford. For more information
about the Company please visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFFTLSIFIIT
(END) Dow Jones Newswires
January 03, 2018 02:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Mar 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024